



## Profound Medical Corp. Opens the Market

**TORONTO, ON (June 15, 2015)** - Profound Medical Corp. (“Profound”) (TSXV: PRN) CEO Steven Plymale and team will join TMX Group representatives today to open the market and recognize Profound’s commencement of trading on TSX Venture Exchange (TSXV) on June 8, 2015 under the symbol “PRN”. Also in attendance will be representatives from BDC Capital Inc., Genesys Capital, GMP Securities L.P., JJR Private Capital and Sunnybrook Hospital.

“This has been a transformational month for Profound Medical – we closed our \$28 Million financing, started trading on TSX Venture Exchange and today we open Toronto Stock Exchange, Canada’s largest capital market. I gratefully acknowledge the countless individuals who made these milestones possible,” says Steve Plymale, CEO, Profound Medical Corp. “We look forward to the day when our procedure will be available to men who have been diagnosed with localized prostate cancer.”

Profound Medical is a medical device company that has developed a unique and minimally invasive treatment to ablate the prostate gland. Profound’s novel technology combines MRI technology with ultrasound thermal energy that is delivered via a transurethral approach. This investigational method of prostate ablative therapy provides highly accurate and precise treatment within the prostate in a short time span, allowing for fast patient recovery. The potential of this technology is currently being assessed in clinical trials.

Please visit Profound’s website at [profoundmedical.com](http://profoundmedical.com) or contact:

Shameze Rampertab  
CFO  
Profound Medical Corp.  
[srampertab@profoundmedical.com](mailto:srampertab@profoundmedical.com)  
T: 647-476-1350, Ext. 424

Or

Rebecca von Goetz  
Senior Marketing & Communications Specialist  
Profound Medical Corp.  
[rvongoetz@profoundmedical.com](mailto:rvongoetz@profoundmedical.com)  
T: 647-476-1350, Ext. 426

\*\*\*\*\*

*Notice regarding forward-looking statements:*

*This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would",*

*"might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.*

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.